Blueprint Medicines Corporation Reports Strong Financial Results for 2024
Blueprint Medicines Corporation, a Delaware-based biopharmaceutical company, recently released its financial results for the year ended December 31, 2024, along with key business highlights. The company reported achieving $479.0 million in global net product revenues from AYVAKIT (avapritinib) in 2024, including $144.1 million in the fourth quarter. Blueprint Medicines also provided financial guidance for 2025, […]
Blueprint Medicines Corporation, a Delaware-based biopharmaceutical company, recently released its financial results for the year ended December 31, 2024, along with key business highlights. The company reported achieving $479.0 million in global net product revenues from AYVAKIT (avapritinib) in 2024, including $144.1 million in the fourth quarter. Blueprint Medicines also provided financial guidance for 2025, […]
